Trial Profile

A double-blind, placebo-controlled multicentre trial of memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 10 Feb 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Memantine (Primary)
Indications Dementia; Lewy body disease; Parkinson's disease
Focus Therapeutic Use
Acronyms MEMPDD

Most Recent Events

09 Feb 2023 This trial has been completed in Sweden, according to European Clinical Trials Database record. (1 Feb 2008)
25 Apr 2015 Pooled analysis results of this trial and other two 24-Week , placebo-controlled trials presented at the 67th Annual Meeting of the American Academy of Neurology.
17 Jul 2013 Secondary endpoint (Clinical Dementia Rating) results presented at the 2013 Alzheimer's Association International Conference .

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com